BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025
(NASDAQ:BCAB), SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) — BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, November 13, 2025 at 4:30 p.m. […]